Compare EHC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHC | PODD |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 10.2B |
| IPO Year | 1994 | 2007 |
| Metric | EHC | PODD |
|---|---|---|
| Price | $127.76 | $141.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 26 |
| Target Price | $148.17 | ★ $167.17 |
| AVG Volume (30 Days) | 880.8K | ★ 1.3M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | ★ 24.22 | N/A |
| EPS | ★ 3.47 | 2.67 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $8.84 | $21.37 |
| Revenue Next Year | $8.26 | $13.57 |
| P/E Ratio | ★ $36.90 | $51.96 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $92.77 | $126.40 |
| 52 Week High | $129.96 | $354.88 |
| Indicator | EHC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 64.54 | 55.87 |
| Support Level | $118.99 | $139.67 |
| Resistance Level | N/A | $143.45 |
| Average True Range (ATR) | 2.66 | 3.53 |
| MACD | 0.50 | 1.15 |
| Stochastic Oscillator | 78.56 | 86.30 |
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.